| Active visfatin is elevated in serum of maintenance haemodialysis patients and correlates inversely with circulating HDL cholesterol. | |
| | |
MedLine Citation:
|
PMID: 19389865 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Increased circulating visfatin may be associated both with endothelial damage and with increased mortality in end-stage renal disease (ESRD). HDL cholesterol is an independent, strong inverse predictor of cardiovascular events. However, associations between visfatin and parameters of lipid metabolism are unclear. Moreover, serum concentrations of visfatin measured by an enzyme immuno assay (EIA) are conflicting and do not correlate with ELISA (enzyme-linked immunosorbent assay) data, which predominantly detect enzymatically active visfatin. METHODS: A total of 74 haemodialysis (HD) patients and 35 control individuals (C) were studied. All subjects (mean age 62.9 years) provided fasted blood samples (HD patients after 66-69 h without dialysis). Circulating visfatin was measured by the ELISA. Body composition was evaluated using waist circumference, skinfold thickness and body impedance analysis. Results obtained by the ELISA were compared with EIA data. RESULTS: Active serum visfatin was increased in HD (5.58 +/- 6.50 ng/ml) versus C [0.97 +/- 1.79 ng/ml, mean +/- SD; P < 0.0001 by multiple regression analysis (MRA)] independently of plasma glucose, serum insulin, diabetes, HDL cholesterol and body composition. Within the HD group, only plasma HDL cholesterol (4% lower per additional mg/dl HDL; P = 0.001) and insulin-treated diabetes mellitus [subgroup of n = 18; 119% higher compared with patients without diabetes (n = 40); P = 0.011] were independently (by MRA) associated with active serum visfatin. Visfatin measured by an EIA showed no correlation with ELISA data. CONCLUSIONS: Our study provides reliable data on active visfatin in HD patients using a well-characterized ELISA. Loss of renal function is accompanied by increased circulating active visfatin concentrations in our patients. Furthermore, decreased HDL cholesterol may hint at an increased probability of cardiovascular events in HD patients with elevated serum visfatin. |
| | |
Authors:
|
Kai-Dietrich Nüsken; Maurice Petrasch; Manfred Rauh; Wolfgang Stöhr; Eva Nüsken; Holm Schneider; Jörg Dötsch |
Related Documents
:
|
10146335 - Plasma exchange for homozygous familial hypercholesterolaemia: the cape town experience. 2084825 - Pyridoxine reduces cholesterol and low-density lipoprotein and increases antithrombin i... 6315035 - The transport of cholesterol through the plasma in normal man. 568675 - Interference of an anesthetic preparation with plasma triglyceride determinations. 2569515 - The effect of hydrotropic agents on the heat coagulation of bovine serum albumin. 12814785 - Branchial and renal handling of urea in the gulf toadfish, opsanus beta: the effect of ... |
Publication Detail:
|
Type: Journal Article Date: 2009-04-23 |
Journal Detail:
|
Title: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association Volume: 24 ISSN: 1460-2385 ISO Abbreviation: Nephrol. Dial. Transplant. Publication Date: 2009 Sep |
Date Detail:
|
Created Date: 2009-08-18 Completed Date: 2009-12-01 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8706402 Medline TA: Nephrol Dial Transplant Country: England |
Other Details:
|
Languages: eng Pagination: 2832-8 Citation Subset: IM |
Affiliation:
|
Department of Pediatrics, University of Erlangen-Nürnberg, Germany. kai-dietrich.nuesken@uk-erlangen.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Body Composition Cardiovascular Diseases / blood, enzymology, etiology Case-Control Studies Cholesterol, HDL / blood* Cytokines / blood* Enzyme-Linked Immunosorbent Assay Female Humans Immunoenzyme Techniques Kidney Failure, Chronic / blood*, complications, enzymology, therapy* Male Middle Aged Nicotinamide Phosphoribosyltransferase / blood* Regression Analysis Renal Dialysis* Risk Factors |
| Chemical | |
Reg. No./Substance:
|
0/Cholesterol, HDL; 0/Cytokines; EC 2.4.2.12/Nicotinamide Phosphoribosyltransferase; EC 2.4.2.12/nicotinamide phosphoribosyltransferase, human |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Glycaemic control in type 2 diabetic patients on chronic haemodialysis: use of a continuous glucose ...
Next Document: Effects of endurance training on extrarenal potassium regulation and exercise performance in patient...